These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16226058)

  • 21. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
    Ohmori T; Ishiwata A; Kashiwakura Y; Madoiwa S; Mitomo K; Suzuki H; Hasegawa M; Mimuro J; Sakata Y
    Mol Ther; 2008 Aug; 16(8):1359-65. PubMed ID: 18523449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
    Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
    Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
    Liu L; Mah C; Fletcher BS
    Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
    Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
    Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
    Ramezani A; Hawley RG
    Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VIII can be synthesized in hemophilia A mice liver by bone marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells.
    Yadav N; Kanjirakkuzhiyil S; Ramakrishnan M; Das TK; Mukhopadhyay A
    Stem Cells Dev; 2012 Jan; 21(1):110-20. PubMed ID: 21480781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
    Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
    Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
    Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
    Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
    VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.